Clinical Trials Directory

Trials / Completed

CompletedNCT01617460

A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder

A Long-term Administration Study of Aripiprazole in Children and Adolescents (Age: 6 to 17 Years) With Autistic Disorder

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
86 (actual)
Sponsor
Otsuka Pharmaceutical Co., Ltd. · Industry
Sex
All
Age
6 Years – 17 Years
Healthy volunteers
Not accepted

Summary

The objective of this study is to investigate the safety and efficacy of aripiprazole orally administered over long term in subjects who complete a short-term treatment study of pediatric Autistic Disorder (031-11-002 study).

Conditions

Interventions

TypeNameDescription
DRUGAripiprazoleFlexibly dose administered orally once daily

Timeline

Start date
2012-09-01
Primary completion
2016-10-01
Completion
2016-10-01
First posted
2012-06-12
Last updated
2024-08-06
Results posted
2017-10-20

Locations

5 sites across 1 country: Japan

Source: ClinicalTrials.gov record NCT01617460. Inclusion in this directory is not an endorsement.

A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder (NCT01617460) · Clinical Trials Directory